EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Decoding the metabolic-immune axis for novel therapeutics in bladder cancer

Meiyan Zhou, Xiaoyan Xue, Huifang Li, Ziqi Chen, Qihong Nie, Yongchang Lai

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-04 · 1881 (2) · 189569

DOI: 10.1016/j.bbcan.2026.189569 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-04. Verfasst von Meiyan Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Administration, School of Medical Business, Guangdong Pharmaceutical University, Guangzhou City 510006, Guangdong Provin…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms. Die Arbeit nennt 213 Literaturangaben. Gefördert von: Zhejiang Traditional Chinese Medicine Administration, Traditional Chinese Medicine Bureau of Guangdong Province, Guangdong Medical Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer is a prevalent malignancy of the urinary system. Urothelial carcinoma is the predominant type, accounting for more than 90% of cases. The remaining histologic types include squamous cell carcinoma (approximately 2%-7%) and adenocarcinoma (approximately 1%-2%). Within urothelial carcinoma, the papillary subtype is responsible for approximately roughly 70% of cases, and it is often linked to high-frequency gene mutations (e.g., FGFR3 and TP53) and epigenetic alterations, such as DNA hypermethylation-mediated silencing of genes, including RASSF1A and CDH1, and disruptions in histone modification attributable to histone deacetylase overexpression. Platinum-based chemotherapy remains the standard first-line treatment for advanced disease. However, recent research efforts have concentrated on targeted therapy, immunotherapy, metabolic reprogramming, and novel biotechnological applications. In particular, the dynamic interplay between tumor cell metabolic reprogramming and the immune suppressive tumor microenvironment, collectively termed the "metabolic-immune axis", constitutes a major challenge underlying drug resistance. This review summarizes how this axis, through mechanisms such as enhanced glycolysis and abnormal amino acid/lipid metabolism, influences bladder cancer progression and treatment responsiveness, thereby establishing a theoretical framework for future research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsHumansTumor MicroenvironmentMetabolic ReprogrammingImmunotherapyAnimalsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Bladder cancerImmunotherapyMetabolic programmingTargeted therapyTumor microenvironment

Autor:innen und Institutionen

  • Department of Pharmaceutical Administration, School of Medical Business, Guangdong Pharmaceutical University, Guangzhou City 510006, Guangdong Province, China.
  • Department of Pharmacy, Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People's Hospital), No. 16 of Meiguan Avenue, Zhanggong District, Ganzhou City 341099, Jiangxi Province, China.
  • Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People's Hospital), No. 16 of Meiguan Avenue, Zhanggong District, Ganzhou City 341099, Jiangxi Province, China. Electronic…
  • Department of Pharmaceutical Administration, School of Medical Business, Guangdong Pharmaceutical University, Guangzhou City 510006, Guangdong Province, China. Electronic address: laiyongzhang@gdpu.edu.cn.

Förderung

  • Zhejiang Traditional Chinese Medicine Administration
  • Traditional Chinese Medicine Bureau of Guangdong Province
  • Guangdong Medical Research Foundation
  • Ganzhou City Bureau of Science and Technology
  • Guangzhou Municipal Science and Technology Project

Zitieren

APA

Zhou, M., Xue, X., Li, H., Chen, Z., Nie, Q., & Lai, Y. (2026). Decoding the metabolic-immune axis for novel therapeutics in bladder cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(2), 189569. https://doi.org/10.1016/j.bbcan.2026.189569

Vancouver

Zhou M, Xue X, Li H, Chen Z, Nie Q, Lai Y. Decoding the metabolic-immune axis for novel therapeutics in bladder cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(2):189569. doi:10.1016/j.bbcan.2026.189569

BibTeX
@article{Zhou2026,
  author = {Zhou, Meiyan and Xue, Xiaoyan and Li, Huifang and Chen, Ziqi and Nie, Qihong and Lai, Yongchang},
  title = {Decoding the metabolic-immune axis for novel therapeutics in bladder cancer},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  volume = {1881},
  number = {2},
  pages = {189569},
  doi = {10.1016/j.bbcan.2026.189569}
}
Kostenlos starten →